BioMarin Deal History & Licensing Activity
BioMarin is a large biotech headquartered in US. Over the past three years, BioMarin has been involved in 5 licensing and acquisition transactions, with a primary focus on Small Molecules (4 deals). The company currently has 32 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
32
Top Modality
Small Molecules
Focus Area
Rare Disease
BioMarin Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BioMarin in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Galafold | Amicus Therapeutics | Small Molecules | Approved | acquisition | Dec 15, 2025 |
BioMarin Pipeline Focus
Therapeutic areas and modalities where BioMarin is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
BioMarin Strategic Signals
Key indicators of BioMarin's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
BioMarin Clinical Pipeline
BioMarin has 32 active clinical trials across 5 development phases.
2
Phase 4
11
Unknown
6
Phase 1
7
Phase 2
6
Phase 3
See How Your Asset Matches BioMarin's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About BioMarin Licensing & Deal Activity
BioMarin is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 5 deals over the past three years, BioMarin ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BioMarin include Rare Disease (14 deals and trials), Rare Disease (6 deals and trials), Autoimmune (1 deal and trial), and Cardiovascular (1 deal and trial). In terms of modality, BioMarin has shown particular interest in small molecules, gene therapy, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BioMarin and 850+ other biopharma companies. Use our Solidus to benchmark your asset against BioMarin's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.